Vimarsana
Biggest News Aggregation in the World

Page 18 - Nuclear Imaging News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Imaging Today - Breaking & Trending Today

Teleradiology Market to Exhibit a Remarkable CAGR of 18.5% - Vimarsana News

Teleradiology Market to Exhibit a Remarkable CAGR of 18.5%

The rise in imaging procedures is expected to drive the demand for teleradiology solutions for reliability and efficiency. Advanced diagnostic imaging,...

Growing Preference for Minimally-invasive Operations - Vimarsana News

Growing Preference for Minimally-invasive Operations

Increasing Adoption of Minimally-Invasive Medical Procedures For Cardiac Disease Treatments, Growing R&D Investments By Government Organizations For The...

Global Nuclear Medicine Market to Reach $8.8 Billion by 2027 - Vimarsana News

Global Nuclear Medicine Market to Reach $8.8 Billion by 2027

/PRNewswire/ -- The "Nuclear Medicine Market- Global Industry Size, Share, Trends, Ciompetition, Opportunity and Forecast, 2017-2027 Segmented By Type, By...

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection - Vimarsana News

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 yearsROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profileCommercial team ready to launch with product available in the fourth quarterBOSTON--(BUSINESS WIRE)--Spe...

Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend (pegfilgrastim - Vimarsana News

Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend (pegfilgrastim

Fresenius Kabi's first approved U.S. biosimilar Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as